Multiplicative effect of serum phosphorus levels and insulin resistance on hypertensive vascular stiffness

 

^* These authors equally contributed as first authors to the work.

• References

• 1 Sciacqua A, Scozzafava A, Pujia A. et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur Heart J 2005; 26: 921-927.
• 2 Perticone F, Ceravolo R, Pujia A. et al. Prognostic significance of endothelial dysfunction in hyper-tensive patients. Circulation 2001; 104: 191-196.
• 3 Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
• 4 Weisinger JR, Bellorín-Font E. Magnesium and phosphorus. Lancet 1998; 352: 391-396.
• 5 Kestenbaum B, Sampson JN, Rudser KD. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
• 6 Dhingra R, Sullivan LM, Fox CS. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
• 7 Foley RN, Collins AJ, Ishani A. et al. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008; 156: 556-563.
• 8 Shuto E, Taketani Y, Tanaka R. et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
• 9 Ix JH, De Boer IH, Peralta CA. et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 04: 609-615.
• 10 Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J Clin Endocrinol Metab 2005; 90: 2823-2827.
• 11 Perticone F, Ceravolo R, Iacopino S. et al. Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients. J Clin Endocrinol Metab 2001; 86: 172-178.
• 12 Sciacqua A, Maio R, Miceli S. et al. Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS one 2012; 07: e44470.
• 13 Perticone M, Maio R, Tassone EJ. et al. Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis 2015; 238: 108-112.
• 14 Avolio AP, Van Bortel LM, Boutouyrie P. et al. Role of pulse pressure amplification in arterial hyper-tension: experts’ opinion and review of the data. Hypertension 2009; 54: 375-383.
• 15 Ceravolo R, Maio R, Pujia A. et al. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. J Am Coll Cardiol 2003; 41: 1753-1758.
• 16 Mancia G, Fagard R, Narkiewicz K. et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hyper-tension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925-1938.
• 17 Ellam T, Wilkie M, Chamberlain J. et al. Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice--brief report. Arterioscler Thromb Vasc Biol 2011; 31: 1988-1990.
• 18 Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004; 44: 112-116.
• 19 Perticone F, Maio R, Sciacqua A. et al. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 2008; 57: 167-171.